X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CIT-013
Therapeutic Area: Immunology Product Name: CIT-013
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: BOM Brabant Ventures
Deal Size: $21.0 million Upfront Cash: Undisclosed
Deal Type: Financing July 02, 2020
Details:
The proceeds will be used to advance the pre-clinical and clinical development of Citryll’s CIT-013 therapeutic antibody, an inhibitor of neutrophil extracellular traps (NETs) and their formation (NETosis).
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
